Universal Cancer Therapy: Tumor-Specific Antibodies for Better Patient Treatment

Our solution is for:

most cancers
all modalities
>900 addressable targets
without targeting healthy tissue

Combotope’s unique and proprietary antibody discovery platform is designed to target aberrant O-glycosylation within the protein context - a modification found in 50-80% of cancers but absent in healthy cells.

Our platform allows for the precise identification of antibodies targeting glycan-protein structures unique to tumor cells, enabling the development of monoclonal antibodies (mAbs) that specifically bind to cancer cells while preserving healthy tissue.

Combotope mAbs comes with different flavors:

they are all tumor-selective but with various target preferences

Truly tumor specific

Highest affinity (pM)

Target-related Ab sequence families

We know precisely….

..how Combotope antibodies binds tumors specifically
..which sequences are in the target-specific family
..which sequences are non-specific

Combotope-D3Y: Our tumor-specific binder for Mucin-1. It selectively stains tumor tissues with high Mucin-1 expression while showing minimal cross-reactivity with other Tn-carrying proteins. The antibody demonstrates an affinity range of 6-20 pM (BLI) and features optimized CDR sequences tailored specifically for the Mucin-1 target protein sequence.

Combotope mAb examples:

Combotope - Tn/STn: A versatile tumor-binding antibody that stains tumor tissues regardless of the specific target protein type. It has an affinity range of 30-60 nM (BLI).

Combotope-D3: A tumor-selective binder for Mucin-1, designed to stain tumor tissues with elevated Mucin-1 expression. Occasional cross-reactivity with other Tn-mucin-like proteins carrying similar epitopes has been observed. This antibody exhibits an affinity range of 20-30 pM (BLI) and includes CDR features specifically suited to the Mucin-1 target protein.

Our partner model is designed for clinical-stage companies to advance the next generation of cancer therapies

Combotope target selection strategy

Combotope will work closely with Partners to identify optimal target selections, revisiting current, previously intractable, and abandoned targets, as well as new targets from Partners.

Combotopes target database contains >900 O-glycosylated membrane proteins

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN

〰️

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️

Combotopes Companion Diagostic Test (CCDx) - verify Tn/STn on selected tumor target.

Combotope provides bioinformatics analysis and deep mining of specific Tn/STn-glycosylations sites to generate multiple binders for each target.

Combotopes Phage Discovery Platform

Identify target-specific antibodies
Generate antibody sequence families for each target

Antibody sequence analysis and discovery workflow

Secured Bioinformatic platforms
Integration and Automation

Our scFv format offers customized Plug'N'Play solutions for partners

IgG mAb

ADC
CAR-T
BiTE’s
Immunocytokine
Radiolabeled
And more

We offer an attractive win-win partnership business model

Upfront, and milestone payments tied to development and regulatory achievements
Minimum royalties and royalties based on product sales.

“By tapping into a wealth of addressable therapeutic targets, we will challenge the boundaries of what’s possible in cancer therapy”

— Søren Jakobsen, founder, COO

“Antibody-based therapies targeting aberrantly glycosylated cancer-specific proteins provide a safer alternative than targeting shared, overexpressed tumor antigens”

— KOL

“We can do things our partners cannot, our partners can do things we cannot, together we do great things”

— Ola Blixt, Inventor, founder, CEO

Leadership

Dr. Klas Ola Blixt

CO-FOUNDER, INVENTOR, & CEO
Ola is the inventor of the Combotope concept and possesses a profound understanding of aberrant glycosylation, enabling the generation of cancer-specific and cancer-selective antibodies. With over 20 years of experience in both basic and applied research across fields such as chemical biology, glycoscience, monoclonal antibodies, and biomarkers, Ola has produced several highly cited publications (h=50) and holds numerous patents. Moreover, Ola brings more than 15 years of management and leadership experience to the table.
Dr. Søren Nyboe Jakobsen

CO-FOUNDER, COO
Søren is the inventor or co-inventor of multiple patents in molecular display, selection techniques, and technologies for detecting and characterizing B and T cells. He is the founder and former CEO of Tetramer Shop, which was successfully acquired by 10x Genomics. Throughout his career, Søren has developed foundational IP, platforms, and products at several notable biotech companies, including Novo Nordisk, Nuevolution (acquired by Amgen), Immudex, PokeACell, and 10x Genomics. With extensive experience in startup management and leadership, Søren has been instrumental in driving innovation across the biotech sector.